Xiamen Kingdomway Group (002626.SZ): has obtained a USA invention patent certificate.

On December 16, Gelonghui reported that Xiamen Kingdomway Group (002626.SZ) announced that the company and its wholly-owned subsidiary Inner Mongolia Kingdomway Pharmaceutical Co., Ltd., as well as its wholly-owned subsidiary Xiamen Kingdomway Biotechnology (Jiangsu) Co., Ltd., recently received an invention patent certificate issued by the USA Patent and Trademark Office. The invention is titled: ANTI-AGING DRUG COMBINATION AND USE THEREOF, patent number: US12,156,882B2. The effective period (protection period) is twenty years (calculated from the date of application). This invention.

Gelonghui FinanceDec 16, 2024 15:46

Xiamen Kingdomway Group (002626.SZ): The recently announced adjustment to the export tax rebate policy does not involve the company's products.

Gelonghui November 20th | Xiamen Kingdomway Group (002626.SZ) stated on the investor interaction platform that the announcement of the adjustment of export tax rebate policy released by the Ministry of Finance and the State Administration of Taxation recently does not involve the company's products.

Gelonghui FinanceNov 20, 2024 11:58

xiamen kingdomway group (002626.SZ): The convertible corporate bonds issued to unspecified entities have been approved and registered by the CSRC.

On November 19, Gelonghui reported that xiamen kingdomway group (002626.SZ) announced that the company recently received the approval from the China Securities Regulatory Commission regarding the registration for the issuance of convertible corporate bonds to unspecified objects (Document No. 1567, 2024). The approval agrees to the company's application for the issuance of convertible corporate bonds to unspecified objects. This approval is valid for 12 months from the date of registration approval.

Gelonghui FinanceNov 19, 2024 16:19

xiamen kingdomway group (002626.SZ): After the completion of the coenzyme Q10 renovation and expansion project, the company's coenzyme Q10 production capacity can reach around 900 tons.

Gelonghui November 13th | xiamen kingdomway group (002626.SZ) stated when receiving specific research on November 13, 2024, that the Coenzyme Q10 retrofit project is progressing as planned, and currently progressing smoothly. After the retrofit is completed, the Coenzyme Q10 production capacity of the company can reach around 900 tons.

Gelonghui FinanceNov 13, 2024 16:18

Xiamen Kingdomway Group (002626.SZ): the company has become the world's largest producer of Coenzyme Q10.

Gelonghui November 13th | Xiamen Kingdomway Group (002626.SZ) stated on November 13, 2024, when receiving specific target research, that as the company's synthetic biological production technology matures, the comprehensive manufacturing cost continues to decrease, and the production cost advantage of Coenzyme Q10 becomes more prominent. With the advantages of high purity, high content, high quality products, as well as the continuous accumulation of the company's brand influence and customer resources, the company has become the world's largest producer of Coenzyme Q10.

Gelonghui FinanceNov 13, 2024 16:17

Xiamen Kingdomway Group (002626.SZ): received 1 invention patent certificate

Gelonghui November 7th | Xiamen Kingdomway Group (002626.SZ) announced that its controlling subsidiary, Jiangsu Chengxin Pharmaceutical Co., Ltd., and its wholly-owned subsidiary, Xiamen Kingdomway Biotechnology (Jiangsu) Co., Ltd., recently received a patent certificate issued by the National Intellectual Property Office for an invention named a method for preparing L-carnosine zinc complex. This invention provides a method for preparing L-carnosine zinc complex. In the complexation reaction stage of the preparation method, water is not required, using a water-free solvent system, reducing the purification difficulty of the product. After solid-liquid separation, the amount of residual solvent in the wet product is small, reducing the difficulty of subsequent granulation.

Gelonghui FinanceNov 7, 2024 15:45